Vitamin B12
Vitamin B12 (Methylcobalamin)
An essential vitamin crucial for energy production, nerve health, red blood cell formation, and cognitive function.
Vitamin B12 is an essential water-soluble vitamin that plays critical roles in neurological function, DNA synthesis, and red blood cell formation. Deficiency is common, especially in vegetarians/vegans, older adults, and those with absorption issues. Methylcobalamin is the active, neurologically-preferred form, while cyanocobalamin is cheaper but requires conversion.
Mechanisms of Action
Methylation Support
Essential cofactor for methionine synthase
Myelin Maintenance
Supports nerve sheath integrity
Red Blood Cell Production
Required for healthy red blood cell formation
Recommended Dose
500-1000mcg daily for maintenance; higher for deficiency
Loading: For deficiency: 1000-2000mcg daily or injections as directed
Optimal Timing
- Morning (may be energizing)
- With or without food
Can be taken without food
Best Form
Methylcobalamin (sublingual)
Alternatives: Adenosylcobalamin, Hydroxocobalamin, Cyanocobalamin (cheapest)
Methylcobalamin is the active form. Sublingual absorption bypasses GI absorption issues.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Sublingual forms bypass absorption issues. Methylcobalamin is preferred for neurological benefits.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Energy Restoration
Improved energy, especially if deficient
Cognitive Support
Better memory and mental clarity
Nerve Health
Prevention/reversal of neurological symptoms
Essential to supplement; B12 only found in animal products
Higher doses often needed due to reduced absorption
Who Should NOT Take This
- Leber's hereditary optic neuropathy (may worsen)
- Cobalt or cobalamin hypersensitivity
Drug Interactions
Metformin reduces B12 absorption; supplementation often needed
Reduce B12 absorption; consider supplementation
Possible Side Effects
Tip: Take with food
Tip: Reduce dose if persistent
Tip: Discontinue if symptoms occur
Warnings
- High-dose B12 can mask folate deficiency symptoms
- Test B12 levels before high-dose supplementation
- Observational studies associate elevated serum B12 levels with increased cancer risk — supplement only if deficient or at risk of deficiency
Top studies from 40+ peer-reviewed papers
Abdelwahab OA et al. • Irish journal of medical science (2024)
“All IM, oral, and SL routes of administration of vitamin B12 can effectively increase the level of vitamin B12 without significant differences between them, as thought previously.”
Key Findings:
- Regarding the hemoglobin level, the pooled effect sizes showed no difference between all routes of administration that could reach statistical significance.
- However, the IM route was the top-ranked statistically but without clinical significance.
- We found no significant difference among studied administrated routes in all other CBC parameters and homocysteine levels.
Zhang N et al. • The American journal of clinical nutrition (2024)
“Our meta-analysis found that the folic acid combined with vitamin B12 and vitamin B6 supplementation strategy significantly reduced the risk of stroke in areas without and with partial folic acid fortification.”
Key Findings:
- In areas without and with partial folic acid fortification, combined B-vitamin supplementation significantly reduced the risk of stroke by 34% [RR: 0.66; 95% confidence interval (CI): 0.50, 0.86] and 11% (RR: 0.89; 95% CI: 0.79, 1.00), respectively.
- Further analysis showed that a dosage of folic acid ≤0.8 mg/d and vitamin B12 ≤0.4 mg/d was best for stroke prevention (RR: 0.65; 95% CI: 0.48, 0.86) in these areas.
- In contrast, no benefit of combined supplementation was found in fortified areas (RR: 1.04; 95% CI: 0.94, 1.16).
Bokayeva K et al. • International journal of molecular sciences (2024)
“Our study provides valuable insights into the nutritional status of PKU patients, but further research is required to confirm these findings and explore additional factors influencing vitamin status in PKU.”
Key Findings:
- The effect sizes were expressed as standardised mean differences.
- The calculation of effect sizes with 95% CI using fixed-effects models and random-effects models was performed.
- A p-value < 0.05 was considered statistically significant.
- PKU patients demonstrated significantly higher folate levels (random-effects model, SMD: 1.378, 95% CI: 0.436, 2.320, p = 0.004) and 1,25-dihydroxyvitamin D concentrations (random-effects model, SMD: 2.059, 95% CI: 0.250, 3.868, p = 0.026) compared to the controls.
Markun S et al. • Nutrients (2021)
“Vitamin B12 supplementation is likely ineffective for improving cognitive function and depressive symptoms in patients without advanced neurological disorders.”
Key Findings:
- Further, meta-regression showed no significant associations of treatment effects with any of the potential predictors.
- We also found no overall effect of vitamin supplementation on measures of depression.
- Further, only one study reported effects on idiopathic fatigue, and therefore, no analysis was possible.
- Vitamin B12 supplementation is likely ineffective for improving cognitive function and depressive symptoms in patients without advanced neurological disorders.
Xia Y et al. • BMJ (Clinical research ed.) (2025)
“Oral methylcobalamin significantly lowered the severity of hand-foot syndrome by reducing the incidence of grade ≥2 symptoms without unexpected safety concerns in women with HER2 negative early breast cancer who were receiving adjuvant capecitabine treatment.”
Key Findings:
- Grade ≥2 hand-foot syndrome occurred in 17 (14.5%) of 117 patients in the methylcobalamin group and 34 (29.1%) of 117 patients in the placebo group (risk difference -14.5%, 95% confidence interval -24.9% to -4.1%; one sided P value=0.003).
- The rate of reduction or discontinuation of capecitabine treatment because of hand-foot syndrome was 7.7% (9 of 117) in the methylcobalamin group and 13.7% (16 of 117) in the placebo group (risk difference -6.0%, 95% confidence interval -13.9% to 1.9%).
- The two groups showed similar incidence of any other adverse events (88 (75.2%) in the methylcobalamin group and 95 (81.2%) in the placebo group).
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.